New Publication: Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Posted in Cancer Cell Biology Program News
New Publication by Sandra Swain, et al.
CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are the established first-line treatment for metastatic and advanced hormone receptor-positive breast cancer (mBC). Recently, there has been an expansion in available next lines of therapy; however, optimal sequencing remains unclear. This paper reviews data on the efficacy and response rates of approved therapeutic options, and when possible, discusses their efficacy in the setting of prior exposure to CDK4/6i. This paper also seeks to review emerging targets and therapeutics that may be approved in the future for this patient population.
Cancers 2023, 15(6), 1855; https://doi.org/10.3390/cancers15061855